1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Lymphoma – Pipeline Review, H1 2013

Lymphoma – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 256 pages

Lymphoma – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lymphoma.
- A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lymphoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lymphoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Lymphoma - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Lymphoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Lymphoma 10
Lymphoma Therapeutics under Development by Companies 12
Lymphoma Therapeutics under Investigation by Universities/Institutes 22
Mid Clinical Stage Products 27
Comparative Analysis 27
Early Clinical Stage Products 28
Comparative Analysis 28
Lymphoma Therapeutics - Products under Development by Companies 30
Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 44
Companies Involved in Lymphoma Therapeutics Development 49
Bristol-Myers Squibb Company 49
Johnson and Johnson 50
Boehringer Ingelheim GmbH 51
F. Hoffmann-La Roche Ltd. 52
Kyowa Hakko Kirin Co., Ltd. 53
Biogen Idec Inc. 54
Shionogi and Co., Ltd. 55
Amgen Inc. 56
Sanofi-Aventis 57
AstraZeneca PLC 58
Eli Lilly and Company 59
GlaxoSmithKline plc 60
Seattle Genetics, Inc. 61
Genentech, Inc. 62
Gilead Sciences, Inc. 63
Daiichi Sankyo Company, Ltd 64
Merck and Co., Inc. 65
Emergent BioSolutions Inc. 66
Gamida Cell Ltd. 67
Infinity Pharmaceuticals, Inc. 68
Reliance Life Sciences Pvt. Ltd. 69
Celltrion, Inc. 70
Bio-Path Holdings, Inc. 71
ZIOPHARM Oncology, Inc. 72
Millennium Pharmaceuticals, Inc. 73
Novartis AG 74
Astellas Pharma Inc. 75
Chong Kun Dang Pharmaceutical 76
Eisai Co., Ltd. 77
Pfizer Inc. 78
SuperGen, Inc. 79
Teva Pharmaceutical Industries Limited 80
Cell Therapeutics, Inc. 81
Genmab A/S 82
Enzon Pharmaceuticals, Inc. 83
Sandoz Inc. 84
Celgene Corporation 85
Onyx Pharmaceuticals, Inc. 86
Bayer AG 87
Merck KGaA 88
4SC AG 89
EpiCept Corporation 90
Celldex Therapeutics, Inc. 91
AEterna Zentaris Inc. 92
IMMUNOMEDICS, INC 93
Idera Pharmaceuticals, Inc. 94
MethylGene Inc 95
Northwest Biotherapeutics, Inc. 96
Cleveland BioLabs, Inc. 97
Curis, Inc. 98
Accentia Biopharmaceuticals, Inc. 99
Telik, Inc. 100
TopoTarget A/S 101
Pharmacyclics, Inc. 102
Progen Pharmaceuticals Limited 103
Green Cross Corporation 104
Panacea Biotec Limited 105
Sareum Holdings plc 106
Innate Pharma SA 107
Spectrum Pharmaceuticals, Inc. 108
Debiopharm Group 109
Chroma Therapeutics Ltd. 110
Chipscreen Biosciences Ltd 111
Memgen, LLC. 112
Multimmune GmbH 113
Nerviano Medical Sciences S.r.l. 114
Aquinox Pharmaceuticals Inc. 115
Aegera Therapeutics Inc. 116
Ascenta Therapeutics, Inc. 117
Cerulean Pharma, Inc. 118
Arno Therapeutics, Inc. 119
Semafore Pharmaceuticals, Inc. 120
Constellation Pharmaceuticals, Inc. 121
MSM Protein Technologies, Inc. 122
Stemline Therapeutics, Inc. 123
Synageva BioPharma Corp. 124
Cornerstone Pharmaceuticals, Inc. 125
Omnitura Therapeutics Inc. 126
Yaupon Therapeutics, Inc. 127
Onconova Therapeutics, Inc 128
TcL Pharma SAS 129
Immune System Therapeutics Ltd. 130
Syndax Pharmaceuticals, Inc. 131
Morphogenesis, Inc. 132
Transtech Pharma, Inc. 133
Xencor, Inc. 134
Acetylon Pharmaceuticals, Inc. 135
iBio, Inc. 136
PharmaMar, S.A. 137
VentiRx Pharmaceuticals, Inc. 138
Kinex Pharmaceuticals, LLC 139
CureTech Ltd. 140
Cylene Pharmaceuticals, Inc. 141
Nereus Pharmaceuticals, Inc. 142
AVEO Pharmaceuticals, Inc. 143
Lytix Biopharma AS 144
KAHR medical Ltd. 145
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. 146
Cancer Therapeutics CRC Pty Ltd 147
EpiZyme, Inc. 148
Helmholtz Zentrum München, GmbH 149
Mebiopharm Co., Ltd. 150
Polaris Group 151
Gliknik, Inc. 152
Shanghai CP Guojian Pharmaceutical Co.,Ltd. 153
Immunovative Therapies, Ltd. 154
PharmaTech International, Inc. 155
Cell>Point 156
Advancell 157
Lymphoma - Therapeutics Assessment 158
Assessment by Monotherapy Products 158
Assessment by Combination Products 159
Drug Profiles 160
StemEx - Drug Profile 160
obinutuzumab - Drug Profile 161
enzastaurin hydrochloride - Drug Profile 162
alisertib - Drug Profile 165
brentuximab vedotin - Drug Profile 168
ibrutinib - Drug Profile 170
BiovaxID - Drug Profile 172
bortezomib - Drug Profile 174
everolimus - Drug Profile 178
mechlorethamine hydrochloride - Drug Profile 180
pralatrexate - Drug Profile 181
lenalidomide - Drug Profile 184
Pixantrone + Rituximab - Drug Profile 186
ofatumumab - Drug Profile 188
ocaratuzumab - Drug Profile 191
DHAP + Rituximab - Drug Profile 193
Rituximab Biosimilar - Drug Profile 194
bortezomib + [cyclophosphamide] + [doxorubicin] + [prednisone] + [rituximab] + [vincristine sulfate] - Drug Profile 195
brentuximab vedotin + [cyclophosphamide] + [doxorubicin] + [prednisone] - Drug Profile 196
rituximab biosimilar + [cyclophosphamide] + [doxorubicin] + [prednisone] + [vincristine sulfate] - Drug Profile 198
Rituximab + Cytarabine + Dexamethasone + Bortezomib - Drug Profile 199
Lymphoma Therapeutics - Drug Profile Updates 201
Lymphoma Therapeutics - Discontinued Products 238
Lymphoma Therapeutics - Dormant Products 241
Lymphoma - Product Development Milestones 253
Featured News and Press Releases 253
Appendix 254
Methodology 254
Coverage 254
Secondary Research 254
Primary Research 254
Expert Panel Validation 254
Contact Us 255
Disclaimer 255



List of Tables

Number of Products Under Development for Lymphoma, H1 2013 11
Products under Development for Lymphoma - Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Development by Companies, H1 2013 (Contd..1) 15
Number of Products under Development by Companies, H1 2013 (Contd..2) 16
Number of Products under Development by Companies, H1 2013 (Contd..3) 17
Number of Products under Development by Companies, H1 2013 (Contd..4) 18
Number of Products under Development by Companies, H1 2013 (Contd..5) 19
Number of Products under Development by Companies, H1 2013 (Contd..6) 20
Number of Products under Development by Companies, H1 2013 (Contd..7) 21
Number of Products under Development by Companies, H1 2013 (Contd..8) 22
Number of Products under Investigation by Universities/Institutes, H1 2013 24
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 25
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 26
Comparative Analysis by Late Stage Development, H1 2013 27
Comparative Analysis by Mid Clinical Stage Development, H1 2013 28
Comparative Analysis by Early Clinical Stage Development, H1 2013 29
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 30
Products under Development by Companies, H1 2013 31
Products under Development by Companies, H1 2013 (Contd..1) 32
Products under Development by Companies, H1 2013 (Contd..2) 33
Products under Development by Companies, H1 2013 (Contd..3) 34
Products under Development by Companies, H1 2013 (Contd..4) 35
Products under Development by Companies, H1 2013 (Contd..5) 36
Products under Development by Companies, H1 2013 (Contd..6) 37
Products under Development by Companies, H1 2013 (Contd..7) 38
Products under Development by Companies, H1 2013 (Contd..8) 39
Products under Development by Companies, H1 2013 (Contd..9) 40
Products under Development by Companies, H1 2013 (Contd..10) 41
Products under Development by Companies, H1 2013 (Contd..11) 42
Products under Development by Companies, H1 2013 (Contd..12) 43
Products under Development by Companies, H1 2013 (Contd..13) 44
Products under Investigation by Universities/Institutes, H1 2013 45
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 46
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 47
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 48
Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 49
Assessment by Monotherapy Products, H1 2013 159
Assessment by Combination Products, H1 2013 160
Lymphoma Therapeutics - Drug Profile Updates 202
Lymphoma Therapeutics - Discontinued Products 239
Lymphoma Therapeutics - Discontinued Products (Contd..1) 240
Lymphoma Therapeutics - Discontinued Products (Contd..2) 241
Lymphoma Therapeutics - Dormant Products 242
Lymphoma Therapeutics - Dormant Products (Contd..1) 243
Lymphoma Therapeutics - Dormant Products (Contd..2) 244
Lymphoma Therapeutics - Dormant Products (Contd..3) 245
Lymphoma Therapeutics - Dormant Products (Contd..4) 246
Lymphoma Therapeutics - Dormant Products (Contd..5) 247
Lymphoma Therapeutics - Dormant Products (Contd..6) 248
Lymphoma Therapeutics - Dormant Products (Contd..7) 249
Lymphoma Therapeutics - Dormant Products (Contd..8) 250
Lymphoma Therapeutics - Dormant Products (Contd..9) 251
Lymphoma Therapeutics - Dormant Products (Contd..10) 252
Lymphoma Therapeutics - Dormant Products (Contd..11) 253



List of Figures

Number of Products under Development for Lymphoma, H1 2013 11
Products under Development for Lymphoma - Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 23
Mid Clinical Stage Products, H1 2013 28
Early Clinical Stage Products, H1 2013 29
Assessment by Monotherapy Products, H1 2013 159
Assessment by Combination Products, H1 2013 160

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Non-Hodgkin’s Lymphoma Therapeutics Market - Growth, Trends and Forecasts (2016 - 2021)

Global Non-Hodgkin’s Lymphoma Therapeutics Market - Growth, Trends and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global non-Hodgkin’s lymphoma treatment market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach ...

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3

  • $ 3500
  • Industry report
  • August 2016
  • by Global Markets Direct

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma ...

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Global Clinical Trials Review, H2, 2016

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • September 2016
  • by Global Data

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Anti-Neutrophil Cytoplasmic Antibody-Associated ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Therapy Market in the US

  • December 2016
    4 pages
  • Cancer  

    Protein  

  • United States  

View report >

Therapy Market in Canada - Forecast

  • December 2016
    63 pages
  • Therapy  

    Monoclonal Anti...  

  • Canada  

View report >

Related Market Segments :

Lymphoma

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.